BioStock: Toleranzia advances its projects despite challenges linked to Covid-19
Toleranzia, that develops potentially curative treatments for severe autoimmune diseases, is, like many other companies, affected by the Covid-19 pandemic. The company recently announced that the planned clinical trial of its drug candidate TOL2 will be postponed until the second half of 2023, due to the fact that the unabated global need for Covid-19 vaccine in the world is causing an extensive shortage of materials needed to purify Toleranzia’s drug candidate. BioStock contacted Toleranzia’s CEO Charlotte Fribert to find out how the company is affected by the delay.
Read the full interview with Charlotte Fribert at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se